[1]沈繼龍,王元元,付 婷,等.國內磷酸肌酸鈉治療冠心病心力衰竭的Meta分析[J].醫學信息,2019,(20):67-71,76.[doi:10.3969/j.issn.1006-1959.2019.20.019]
 SHEN Ji-long,WANG Yuan-yuan,FU Ting,et al.Meta-analysis of Sodium Creatine Phosphate in the Treatment of Coronary Heart Disease with Heart Failure in China[J].Medical Information,2019,(20):67-71,76.[doi:10.3969/j.issn.1006-1959.2019.20.019]
點擊復制

國內磷酸肌酸鈉治療冠心病心力衰竭的Meta分析()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
67-71,76
欄目:
論著
出版日期:
2019-10-15

文章信息/Info

Title:
Meta-analysis of Sodium Creatine Phosphate in the Treatment of Coronary Heart Disease with Heart Failure in China
文章編號:
1006-1959(2019)20-0067-06
作者:
沈繼龍王元元付 婷周情太汪明燈
(南京醫科大學附屬蘇州科技城醫院重癥醫學科,江蘇 蘇州 215153)
Author(s):
SHEN Ji-longWANG Yuan-yuanFU TingZHOU Qing-taiWANG Ming-deng
(Department of ICU,Suzhou Science and Technology Hospital,Nanjing Medical University,Suzhou 215153,Jiangsu,China)
關鍵詞:
冠心病心力衰竭Meta分析磷酸肌酸鈉
Keywords:
Coronary heart diseaseHeart failureMeta-analysisSodium creatine phosphate
分類號:
R541.4;R541.6
DOI:
10.3969/j.issn.1006-1959.2019.20.019
文獻標志碼:
A
摘要:
目的 采用Meta分析評價國內磷酸肌酸鈉對冠心病心力衰竭的臨床療效。方法 計算機檢索中國期刊全文數據庫、中國生物醫學文獻數據庫、維普中文期刊及萬方數據庫中關于磷酸肌酸鈉治療冠心病心力衰竭的研究報道。文獻檢索時限為建庫至2018年12月。采用RevMan5.3軟件對納入的文獻數據進行Meta分析。結果 共納入文獻16篇,累計1448例患者。Meta分析結果顯示:①總體療效評價:磷酸肌酸鈉組治療冠心病心力衰竭的臨床療效高于常規治療組(OR=4.93,95%CI 3.47~7.01,P<0.001);②不同療程療效評價:療程14 d時,磷酸肌酸鈉組比常規治療組能更有效的改善冠心病心力衰竭患者的心臟功能(OR=6.34,95%CI 3.90~10.29,P<0.001);療程<14 d時,磷酸肌酸鈉組改善冠心病心力衰竭患者的心功能與常規治療組比較,差異不顯著(OR=2.57,95%CI 1.29~5.09,P>0.001);療程>14 d時,磷酸肌酸鈉組比常規治療組能更有效的改善冠心病心力衰竭患者的心臟功能(OR=5.44,95%CI 2.42~12.23,P<0.001)。③劑量療效評價:對療程14 d的9項研究根據不同劑量進行亞組分析,劑量為1 g ivgtt qd時,磷酸肌酸鈉組改善冠心病心力衰竭患者的心功能與常規治療組比較,差異不顯著(OR=4.87,95%CI 1.7~13.98,P>0.001);劑量為1 g ivgtt bid時,磷酸肌酸鈉組比常規治療組能更有效的改善冠心病心力衰竭患者的心臟功能(OR=9.73,95%CI 4.05~23.40,P<0.001);劑量為2 g ivgtt qd時,磷酸肌酸鈉組比常規治療組能更有效的改善冠心病心力衰竭患者的心臟功能(OR=6.11,95%CI 2.93~12.72,P<0.001);同時1 g bid劑量的改善效果優于2 g bid和1 g qd。結論 磷酸肌酸鈉能夠緩解冠心病心力衰竭患者臨床癥狀,改善心功能,具有一定的臨床療效,同時磷酸肌酸鈉改善冠心病心力衰竭患者心功能的效果與給藥劑量和次數有一定的相關性。
Abstract:
Objective Meta-analysis was used to evaluate the clinical efficacy of sodium creatine phosphate in patients with coronary heart disease and heart failure. Methods Computer-researched Chinese Journal Full-text Database, China Biomedical Literature Database, Weipu Chinese Journal and Wanfang Database reported on the treatment of coronary heart disease with heart failure by sodium creatine phosphate. The time limit for document retrieval is to build the library until December 2018. Meta-analysis of the included literature data was performed using RevMan 5.3 software. Results A total of 16 articles were included in the literature, with a total of 1448 patients. Meta-analysis results showed:①Overall efficacy evaluation: The clinical efficacy of sodium creatine phosphate group in the treatment of coronary heart disease with heart failure was significantly higher than that of the conventional treatment group (OR=4.93, 95%CI3.47~7.01, P<0.001); ②Efficacy evaluation of different courses of treatment: At 14 d of treatment, the sodium creatine phosphate group was more effective than the conventional treatment group in improving cardiac function in patients with coronary heart disease (OR=6.34, 95%CI3.90~10.29,P<0.001); When the course of treatment was <14 d, the cardiac function of patients with heart failure in patients with coronary heart disease was significantly different from that of the conventional treatment group (OR=2.57, 95%CI1.29~5.09, P>0.001). When the course of treatment was >14 d, The sodium creatine phosphate group was more effective than the conventional treatment group in improving cardiac function in patients with coronary heart disease (OR=5.44, 95%CI2.42~12.23, P<0.001). ③Evaluation of different doses of efficacy: 9 cases of 14 d of treatment were subgroup analysis according to different doses. When the dose was 1 g ivgtt qd, the difference of cardiac function between patients with heart disease and coronary heart disease was significantly different from that of conventional treatment group. (OR=4.87, 95%CI1.7~13.98, P>0.001); at the dose of 1 g ivgtt bid, the sodium creatine phosphate group was more effective than the conventional treatment group in improving cardiac function in patients with coronary heart disease (OR= 9.73, 95%CI4.05~23.40,P<0.001); when the dose was 2 g ivgtt qd, the sodium creatine phosphate group was more effective than the conventional treatment group in improving cardiac function in patients with coronary heart disease (OR=6.11, 95%CI2.93~12.72, P<0.001); the improvement of 1 g bid dose was better than 2 g qd and 1 g qd. Conclusion Sodium creatine phosphate can alleviate the clinical symptoms of patients with coronary heart disease and improve cardiac function, and has certain clinical efficacy. At the same time, the effect of sodium creatine phosphate on improving cardiac function in patients with coronary heart disease and heart failure has a certain correlation with the dose and frequency of administration.

參考文獻/References:

[1]楊菲菲,智光,王秋霜.肺部超聲在心力衰竭應用中的研究進展[J].中華老年心腦血管病雜志,2017,19(3):325-327. [2]黃峻.中國心力衰竭流行病學特點和防治策略[J].中華心臟與心律電子雜志,2015,3(2):2-3. [3]Gustafsson F,Rogers JG.Left ventricular assist device therapy in advanced heart failure:patient selection and outcomes[J].Eur J Heart Fail,2017,19(5):595-602. [4]Pocock SJ,Wang D,Pfeffer MA,et al.Predictors of mortality and morbidity in patients with chronic heart failure[J].Eur Heart J,2006,27(1):65-75. [5]倪晶宇,李瀾,李敏,等.慢性心力衰竭與能量代謝重構關系的研究進展[J].中國臨床藥理學雜志,2017,33(5):474-477. [6]黃曉渝,魯桓,孟麗琴,等.磷酸肌酸鈉治療急性心肌梗死心力衰竭的臨床觀察[J].現代醫藥衛生,2010,26(15):2261-2262. [7]李作成.注射用磷酸肌酸鈉治療急性心肌梗死后心力衰竭的療效[J].中國老年學雜志,2010,30(16):2371-2372. [8]鄧恩平,黃漢光,李艷.磷酸肌酸鈉治療冠心病合并心力衰竭療效觀察[J].海南醫學,2011,22(3):88-89. [9]張灼輝,譚健強,蘇小紅.注射用磷酸肌酸鈉治療冠心病慢性充血性心力衰竭[J].中西醫結合心腦血管病雜志,2011,9(7):772-773. [10]黎軍德,左梅.磷酸肌酸鈉治療老年冠心病心力衰竭療效觀察[J].吉林醫學,2011,32(29):6119-6120. [11]滕偉,薛永亮,何兆輝,等.磷酸肌酸鈉對冠心病并慢性心力衰竭患者B型利鈉肽及心功能的影響[J].中國醫藥導報,2012,9(18):59-60. [12]陳紅梅,徐開聯,付延導.磷酸肌酸鈉在治療冠心病合并心力衰竭的應用研究[J].當代醫學,2012,18(17):133-134. [13]王愛琴.磷酸肌酸鈉治療51例冠心病合并心力衰竭的療效觀察[J].中國醫學創新,2013,10(3):130-131. [14]楊瑗.磷酸肌酸鈉治療老年冠心病心力衰竭療效觀察[J].醫藥論壇雜志,2013,34(9):104-105. [15]劉園園.注射用磷酸肌酸鈉治療51例冠心病合并慢性充血性心力衰竭的療效觀察[J].中國傷殘醫學,2013,21(4):156-157. [16]張玉紅.觀察注射用磷酸肌酸鈉治療急性心肌梗死后心力衰竭的療效[J].中外醫療,2013,32(16):108,110. [17]張道全,高建忠,布和.注射用磷酸肌酸鈉治療冠心病并慢性心力衰竭的療效觀察[J].中國實用醫藥,2014(10):142-143. [18]王萬里.磷酸肌酸鈉治療冠心病合并心力衰竭的療效能對心功能的改善作用[J].中西醫結合心血管病雜志(電子版),2015,3(16):17-18. [19]周徐洲,蘇倬杰,陳偉亮.急性心肌梗死后心力衰竭患者使用磷酸肌酸鈉的效果[J].牡丹江醫學院學報,2016,37(4):61-62. [20]張良芬,趙韻超.磷酸肌酸鈉治療高齡冠心病合并心力衰竭的體會[J].世界最新醫學信息文摘(電子版),2016(32):13-14. [21]王珊珊,張紅,陳穗,等.磷酸肌酸鈉治療老年冠狀動脈粥樣硬化性心臟病舒張性心力衰竭的臨床效果[J].中國醫藥,2016,11(2):154-157. [22]Gaddi AV,Galuppo P,Yang J.Creatine Phosphate Administration in Cell Energy Impairment Conditions: A Summary of Past and Present Research[J].Heart Lung Circ,2017(17):1-10. [23]田帥,張利宣,馬子健,等.慢性心力衰竭患者應用磷酸肌酸鈉治療對心功能和NT-probnp的影響[J].河北醫藥,2016,38(14):2173-2175. [24]劉狀.磷酸肌酸鈉治療慢性心力衰竭療效及對患者血清相關細胞因子水平的影響[J].醫學臨床研究,2018,35(11):2164-2166. [25]張彬,趙宏.磷酸肌酸的心肌保護機制及其在心臟疾病中的應用[J].醫學綜述,2008,14(2):262-264. [26]王波,歐陽艷紅,方小麗,等.苦碟子聯合磷酸肌酸鈉對冠心病合并心力衰竭患者血清脂聯素水平及心功能的影響[J].中國老年學雜志,2015,36(19):5510-5512. [27]汪硯雨,欒琴.磷酸肌酸鈉對慢性心力衰竭患者CgA、BNP等指標水平的影響[J].實驗與檢驗醫學,2017,35(4):952,954-602. [28]陳佳怡.注射用磷酸肌酸鈉在冠狀動脈搭橋術圍手術期的心肌保護作用[J].中外醫學研究,2017,15(13):31-32. [29]趙文靜,侯榮華,劉婷,等.磷酸肌酸鈉治療原發性肝癌介入術后所致心肌損傷的療效分析[J].現代腫瘤醫學,2016,24(16):2568-2570. [30]尹成芳.丹紅注射液聯合磷酸肌酸鈉治療慢性心力衰竭病人的療效及不良反應分析[J].內蒙古醫科大學學報,2019,41(4):429-431. [31]勾振山.磷酸肌酸鈉對急診PCI 術中缺血再灌注心肌的保護作用研究[J].黑龍江醫藥,2019,32(4):807-808. [32]Ying W,Chen Y.Efficiency of Creatine Phosphate Sodium and Hyzaar in hypertensive patients withdiastolic dysfunction[J].Heart,2013,99(suppl3):A222. [33]Wang FR,Zheng X.Effects of phosphocreatine on plasma brain natriuretic peptide level and left ventricular function in patients with heart failure[J].PJCCPVD,2008(16):29-31. [34]周德明,陳明,張小明.磷酸肌酸鈉對高齡嚴重肺部感染并發心力衰竭患者心肌酶及B型尿鈉肽的影響[J].貴州醫藥,2019,43(7):1071-1072. [35]劉寧,劉吳,白華,等.芪藶強心膠囊聯合磷酸肌酸對冠心病合并心力衰竭病人血清脂聯素與心功能的影響[J].中西醫結合心腦血管病雜志,2016,14(7):673-675. [36]周沃聯,黃琪述,周麗華,等.磷酸肌酸鈉對老年心力衰竭患者血清超敏C反應蛋白、同型半胱氨酸、BNP的影響[J].中國現代藥物應用,2016,10(11):194-195.

相似文獻/References:

[1]郭俊林,張立.BNP對CRT后期療效的臨床評價[J].醫學信息,2018,(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
 GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,(20):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]袁 帥,邢曉博,李 曉,等.MTHFR基因多態性與中年男性冠狀動脈病變程度的相關研究[J].醫學信息,2018,(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
 YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,(20):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[3]張挺挺.經股和橈動脈介入治療冠心病的臨床療效對比[J].醫學信息,2018,(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
 ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,(20):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[4]迮艷華.穩心顆粒聯合美托洛爾治療冠心病心律失常的療效分析[J].醫學信息,2018,(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
 ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,(20):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[5]張 旭.冠心病心絞痛患者進行護理干預的臨床效果及 對護理質量影響研究[J].醫學信息,2018,(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
 ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,(20):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[6]向明明,趙曉輝.黑龍江省東部地區漢族人群冠心病的危險因素研究[J].醫學信息,2018,(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
 XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,(20):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[7]王 坤,張永春.血清膽紅素水平、單核細胞數、紅細胞分布寬度與 冠狀動脈病變程度的關系[J].醫學信息,2018,(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
 WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,(20):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[8]程 林.重組人腦利鈉肽用于重癥急性心肌炎伴 心力衰竭患者治療的臨床研究[J].醫學信息,2018,(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
 CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,(20):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[9]胡麗君.螺內酯聯合曲美他嗪治療慢性心力衰竭的療效分析[J].醫學信息,2018,(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
 HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,(20):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[10]毛紅巖.冠狀動脈介入治療冠心病的療效及 對患者血清炎癥因子的影響[J].醫學信息,2018,(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
 MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,(20):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[11]李 鐸,王建華.鹽酸曲美他嗪片輔助治療對冠心病伴心力衰竭患者氧化應激、心肌功能的影響[J].醫學信息,2018,(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
 LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,(20):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[12]何玲玲,程淑芬.曲美他嗪聯合琥珀酸美托洛爾治療冠心病心力衰竭療效觀察[J].醫學信息,2018,(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
 HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,(20):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[13]紀東華.曲美他嗪治療老年冠心病心力衰竭的療效及其對患者 炎癥因子的影響[J].醫學信息,2019,(13):141.[doi:10.3969/j.issn.1006-1959.2019.13.043]
 JI Dong-hua.Efficacy of Trimetazidine in the Treatment of Elderly Patients with Coronary Heart Disease and Its Effect on Inflammatory Factors[J].Medical Information,2019,(20):141.[doi:10.3969/j.issn.1006-1959.2019.13.043]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图